{
	"kja6indxText": "Bibliograp<span class=\"_ _0\"></span>hy",
	"kja6indyText": "<ul style=\"list-style-type: none; margin: 0px; padding: 0px; line-height: 1.15;\"><li style=\"margin-bottom: 1px;\"><font style=\"font-size: 24px;\">Albinet CT et al. Brain Cogn 2012;79:1-11.\nAlvarez E et al. Int J Neuropsychopharmacol 2012;15:589-600.\nAmerican Psychiatric Association. Practice Guideline for the Treatment of\nPatients with Major Depressive Disorder. Third Edition. 2010.\nAmerican Psychiatric Association Diagnostical and Statistical Manual for Mental\ndisorders. Fifth Edition (DSM-5). 2013.\nAmerican Psychiatric Association Publishing Textbook of Psychopharmacology.\nFifth Edition. Chapter 16. Vortioxetine\nBaldwin DS et al. J Psychopharmacol 2016;30:242-252.\nBaune BT et al. Int J Neuropsychopharmacol 2018;21:97-107.\nBoulenger JP et al. J Psychopharmacol 2012;26:1408-1416.\nBrintellix® Summary of Product Characteristics. 2021.\nBryant J et al. PLoS One 2017;12:e0173439.\nCao B et al. Front Psychiatry 2019;10:1-8.\nChin CN et al. Curr Med Res Opin 2018;34:1975-1984.\nChokka P et al. CNS Spectr 2019;24:338-347.\nChokka P et al. CNS Spectr 2019;25;1-12.\nChristensen MC et al. J Psychopharmacol 2018;32:1086-1097\nChristensen MC et al. J Affect Disord 2020;263:258-266.\nChristensen MC et al. CNS Spectr. 2021 Oct 18;1-26. doi: 10.1017/\nS1092852921000936.\nChristensen MC et al. Poster presented at ECNP. P.0073. 2021.\nCipralex® Summary of Product Characteristics. 2020.\nCipriani A et al. Lancet 2018;391:1357-1366.\nClayton AH et al. Expert Opin Drug Saf 2014;13:1361-1374.\nConradi HJ et al. Psychol Med 2011;41:1165-1174.\nEffexor® Summary of Product Characteristics. 2020.\nFagiolini A et al. Poster presented at ECNP. 2020.\nFagiolini A et al. J Affect Disord 2021;283:472-479.\nFehnel S et al. CNS Spectr 2016;21:43-52.\nFlorea l et al. Brain Behav 2017;7:e00622.\nFranken IHA et al. J Affect Disord 2007;99:83-89.\nGoodwin GM et al. J Affect Disord 2017;221:31-35.\nGreer T et al. CNS Drugs 2010;24:267-284.\nHammar A, Ardal G. Front Hum Neurosci 2009;3:26.\nHammer-Helmich L et al. Neuropsychiatr Dis Treat 2018;9:239-249.\nHaro JM et al. Neuropsychiatr Dis Treat 2019; 15:2313-2323.\nJacobsen PL et al. Int Clin Psychopharmacol 2015;30:225-264.\nJaeger J et al. Psych Res 2006;145:39-48.\nJakobsen JC et al. BMC Psychiatry 2017;17:58.\nKatona C et al. Int Clin Pyschopharmacol 2012;27:215-223.<br style=\"\"></font></li><li style=\"margin-bottom: 1px;\"><font style=\"font-size: 24px;\">Kelly K, et al. Dialogues Clin Neurosci 2008;10:409-418.\nLezak M. Neuropsychological Assessment 3rd ed. New York: Oxford University\nPress. 1995.</font><br></li><li style=\"margin-bottom: 1px;\"><font style=\"font-size: 24px;\">Llorca PM et al. Curr MedRes Opin 2014;30:12,2589-2606.<br></font></li></ul>",
	"kja6indzText": "<ul style=\"list-style-type: none; margin: 0px; padding: 0px; line-height: 1.15;\"><li style=\"margin-bottom: 1px;\"><font style=\"font-size: 24px;\">Mahableshwarkar AR et al. Neuropsychopharmacol 2015;40:2025-2037.\nManit et al. Clin Pract Epidemiology Ment Health 2017;13:185-199.\nMarazziti D et al. Eur J Pharmacol 2010;626:83-86.\nMattingly G et al. Poster presented at ECNP. P.0724. 2021.\nMcClintock SM et al. J Clin Psychopharmacol 2011;31:180-186.\nMcCue M et al. BMC Psychiatry. 2021;21(1):622.\nMcIntyre RS et al. Int J Neuropsychopharmacol 2014;17:1557-1567.\nMcIntyre RS et al. CNS Drugs 2015;29:577-589.\nMcIntyre RS et al. Int J Neuropsychopharmacol 2016;19:1-9.\nMcIntyre RS et al. J Clin Psychiatry 2017;78:115-121.\nMcIntyre RS et al. Neuropsychiatr Dis Treat 2021;17:575-585.\nMcNaughton EC et al. Patient Prefer Adherence 2019;13:959-967.\nMontgomery SA, Asberg M. Brit Pyschiatry 1979;134:382-389.\nMontgomery SA et al. Hum Psychopharmacol Clin Exp 2014;29:470-482.\nNutt D et al. J Psychopharmacol 2007;21:461-471.\nOlfson M et al. Am J Psychiatry 1997;154:1734-1740.\nPan <span style='font-family:Arial;color:rgb(100,94,94);'>Z</span> et al. Curr Pharm Des 2017;23:2065-2072.\nPatterson TL et al. Schizophrenia Bull 2001;27:235-245.\nPaykel ES et al. Psychol Med 1995;25:1171-1180.\nPrice J et al. J Affect Disord 2012;140:66-74.\nRead J et al. Psychiatry Res 2014;216:67-73.\nRush AJ et al. Am J Psychiatry 2006;163:1905-1917.\nSaragoussi D et al. Neuropsychiatr Dis Treat 2017;13:2151-2165.\nSaragoussi D et al. Poster presented at the American Psyciatic Association 16th\nAnnual Meeting. May 14-18.2016.\nSeroxat® Summary of Product Characteristics. 2019.\nShahid A et al. Motivation and Energy Inventory (MEI). In: Shahid A et al, Eds.\nSTOP, THAT and One Hundred Other Sleep Scales. Springer, 2014.<br style=\"\"></font></li><li style=\"margin-bottom:1px;\"><font style=\"font-size: 24px;\">Sheehan KH, Sheehan DV. Int Clin Psychopharmacol 2008;23:70-83.\nSnaith RP et al. Br J Psychiatry 1995;167:99-103.\nSubramaniapillai M et al. Compr Psychiatry 2019;94:152113.\nTaylor et al. Maudsley Prescribing Guidelines. 13th Edition. 2018.\nThase ME et al. Eur Neuropsychopharmacol 2016;26:979-993.\nThase ME et al. Eur Neuropsychopharmacol 2017;27:773-781.\nTreadway MT et al. PLoS One. 2009;4:e6598.\nTrintellix® US Prescribing Information.\nTrivedi MH et al. Am J Psychiatry 2006;163:28-40.\nUniversity of Oxford. The Oxford Depression Questionnaire (OPQ). Available\nat: https://innovation.ox.ac.uk/outcome-measures/the-oxford-depression</font></li><li style=\"margin-bottom:1px;\"><font style=\"font-size: 24px;\">questionnaire-odq/\nValdoxan® Summary of Product Characteristics. 2020.\nVieta E et al. Eur Neuropsychopharmacol 2017;27:877-884.\nViibryd® Summary of Product Characteristics. 2014.\nWang G et al. Curr Med Res Opin 2015;31:785-794.<br style=\"\"></font></li><li style=\"margin-bottom:1px;\"><br style=\"\"></li></ul>",
	"kja6ine1Text": "PI                                              <span style=\"color: rgb(255, 255, 255);\">Bibliography</span><span class=\"_ _18\"> </span>"
}
